Is Docetaxel Essential for Darolutamide‐Based Metastatic Hormone‐Sensitive Prostate Cancer Therapy?

Dr. Yasuhisa Fujii is an Editorial Board member of the International Journal of Urology and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.